StockData

Axsome Therapeutics vs Vanda Pharmaceuticals

AXSM and VNDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AXSM and VNDA compare

Axsome Therapeutics is the larger company, worth 31 times as much as Vanda Pharmaceuticals ($7.1B against $230M).

Axsome Therapeutics grew revenue faster over the last twelve months (56.9% versus 8.1% for Vanda Pharmaceuticals).

Axsome Therapeutics keeps more of each dollar of sales as profit, with a net margin of −24.7% compared with −120% at Vanda Pharmaceuticals.

Vanda Pharmaceuticals scores higher on the StockData Score (10 against 8 for Axsome Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAXSMVNDA
Size and price
Market cap$7.1B$230M
Share price$135.95$3.81
Change, 1 year−2.7%−12.4%
Change, 5 years268%−77.0%
Beta (5Y)0.870.78
Employees500533
StockData Score
Total score810 (better)
Valuation score03 (better)
Growth score3 (better)2
Performance score2 (better)0
Health score35 (better)
Dividend score00
Valuation
P/S9.2×1.0× (better)
P/B85.5×1.2× (better)
FCF yield−1.0% (better)−60.8%
Fair value–$8.53
Margin of safety–55.3%
Growth
Revenue growth (TTM)56.9% (better)8.1%
Revenue growth, 5Y average–−2.7%
Profitability
Gross margin93.2%93.6% (better)
Operating margin−24.0% (better)−77.6%
Net margin−24.7% (better)−120%
FCF margin−9.3% (better)−61.0%
Return on equity−245%−82.5% (better)
Return on invested capital–−52.6%
Financial health
Debt / equity2.26 (better)0.00
Current ratio1.431.54 (better)
Altman Z-score4.21 (better)−1.85
Piotroski F-score5 (better)3
Dividends and buybacks
Buyback yield−0.50%–
Shareholder yield−0.50%0.00% (better)
Ownership
Held by institutions73.8%82.2%
Held by insiders15.2%9.2%
Insider net buying, 12 months−$113M−$2.8M (better)
Short interest, % of float7.3%13.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.